Treating Early-Stage Esophageal Cancer: When Endoscopy Can Replace Surgery

Early esophageal cancer, defined clinically as T1 N0 disease, opens up a treatment option that locally advanced disease doesn't: managing the cancer through the endoscope alone, without ever going to the operating table. But it only works within fairly specific limits.

What Counts as Early Disease

T1 N0 disease can be further split into T1a, where the tumour extends only up to the muscularis mucosa, and T1b, where it reaches the submucosa but has not yet crossed into the muscularis propria. Both are node-negative by definition.

What Rules Endoscopic Treatment Out

Three factors rule endoscopic management out immediately: a poorly differentiated tumour, since these are not feasible candidates for ablation or resection regardless of size; a T2 lesion, which is excluded outright; and any node-positive disease, which should not be considered for endoscopic treatment at all.

Matching the Technique to the Lesion

Within eligible T1a disease, the approach depends on the lesion's appearance and size. An intramucosal lesion that is carcinoma in situ or limited to the lamina propria, and well or moderately differentiated, can be treated this way. A flat, high-grade dysplastic or intramucosal lesion limited to the lamina propria can be ablated or resected endoscopically, but a nodular lesion needs EMR outright, ablation alone is not sufficient for it. Where disease extends to the muscularis propria, EMR or ESD is advisable regardless of how far it extends, with EMR preferred for lesions under 2 cm and ESD preferred above that. For squamous cell carcinoma specifically, a T1a lesion with early mucosal invasion under 15 mm favours EMR, while one over 15 mm favours ESD, and disease reaching the inner lining of the muscularis propria carries a higher risk of nodal recurrence, which is why endoscopic management is usually avoided at that depth.

When Submucosal Invasion Still Allows Endoscopy

Even once the submucosa is involved, endoscopy can sometimes still be offered. A T1b adenocarcinoma with submucosal invasion under 500 microns, or a squamous cell carcinoma with submucosal involvement under 200 microns, can both still be managed endoscopically, though both carry a genuinely higher risk of lymph node metastasis that the patient needs to understand and accept surveillance for.

What This Looks Like in Practice

In practice, a T1a lesion under 2 cm that is well or moderately differentiated is offered endoscopic treatment, provided the patient understands and accepts the need for ongoing surveillance. For every other case, surgery is the preferred route, unless the patient isn't fit enough to undergo an esophagectomy. As a rough rule of thumb for T1b disease specifically, a lesion under 1.5 cm can go straight to EMR followed by a multidisciplinary discussion on whether further treatment is needed, while anything larger than 1.5 cm needs an explicit ESD-versus-esophagectomy decision made upfront.

This article is based on a Jivo Masterclass session conducted by Dr. Preeti Vijayakumaran, Consultant, Surgical Oncology, Artemis Hospital, Gurugram. The article has been summarised with the assistance of an AI tool from the original masterclass recording. Watch the full Masterclass recording